Compare SANA & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SANA | SLRC |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 793.1M | 803.0M |
| IPO Year | 2021 | 2007 |
| Metric | SANA | SLRC |
|---|---|---|
| Price | $3.63 | $12.65 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 7 |
| Target Price | $7.80 | ★ $15.14 |
| AVG Volume (30 Days) | ★ 2.3M | 422.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.49% |
| EPS Growth | ★ 17.24 | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $26.96 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.61 | $12.13 |
| 52 Week High | $6.55 | $16.75 |
| Indicator | SANA | SLRC |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 45.13 |
| Support Level | $3.62 | $12.47 |
| Resistance Level | $3.75 | $13.33 |
| Average True Range (ATR) | 0.20 | 0.29 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 72.56 | 28.97 |
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.